DOCSLIB.ORG

E75-Vaccine Composition for Mucosal Administration

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
E75-Vaccine Composition for Mucosal Administration (19) TZZ ___T (11) EP 2 762 161 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 06.08.2014 Bulletin 2014/32 A61K 39/00 (2006.01) (21) Application number: 14000326.0 (22) Date of filing: 29.01.2014 (84) Designated Contracting States: • Okubo, Katsuyuki AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Ibaraki-shi, GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Osaka 567-8680 (JP) PL PT RO RS SE SI SK SM TR • Maeda, Yoshiki Designated Extension States: Ibaraki-shi, BA ME Osaka 567-8680 (JP) • Shishido, Takuya (30) Priority: 05.02.2013 JP 2013020909 Ibaraki-shi, Osaka 567-8680 (JP) (71) Applicant: NITTO DENKO CORPORATION • Li, Wenjing Ibaraki-shi, Ibaraki-shi, Osaka 567-8680 (JP) Osaka 567-8680 (JP) • Hori, Mitsuhiko (72) Inventors: Ibaraki-shi, •Asari,Daisuke Osaka 567-8680 (JP) Ibaraki-shi, •Sugiyama,Haruo Osaka 567-8680 (JP) Suita-shi, • Okazaki, Arimichi Osaka 565-0871 (JP) Ibaraki-shi, Osaka 567-8680 (JP) (74) Representative: Müller-Boré & Partner • Matsushita, Kyohei Patentanwälte PartG mbB Ibaraki-shi, Friedenheimer Brücke 21 Osaka 567-8680 (JP) 80639 München (DE) (54) E75-vaccine composition for mucosal administration (57) The present invention provides a cancer vaccine composition for mucosal administration comprising (i) a HER2/neu E75 peptide and/or a modified HER2/neu E75 peptide; and (ii) a first cellular immunity induction promoter. EP 2 762 161 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 762 161 A1 Description TECHNICAL FIELD 5 [0001] The present invention relates to a cancer vaccine for mucosal administration comprising a HER2 antigen peptide, particularly a HER2/neu E75 peptide and/or a modified HER2/neu E75 peptide, and a cellular immunity induction promoter. BACKGROUND ART 10 [0002] There are a cancer vaccine that prevents viral infection to prevent a cancer caused by the virus, and a cancer vaccine which provides the result that cancer cells are specifically attacked by the immune system via the recognition of a cancer-specific antigen by the immune mechanism, particularly the cellular immune mechanism in which cytotoxic T cells (CTLs) play an important role. The former is not effective at all for a cancer in which the virus does not participate. 15 The latter is a cancer therapeutic strategy of targeting an antigen possessed by a cancer cell itself. It is considered that the latter is widely effective for cancers having antigen by specifying the antigen. Inter alia, a cancer vaccine based on the viewpoint of the latter can treat tumors that are difficult to remove by surgical operation because of their size, and causes less side effects as compared with the conventional therapies such as chemotherapy and radiation therapy. [0003] A HER2/neu gene is amplified and overexpressed in various adenocarcinomas including breast cancer. Those 20 cancers overproduce the HER2/neu protein. The HER2/neu protein is fragmented in the cancer cell to produce partial peptides containing 8 to 12 amino acids. A HER2/neu peptide is one of the peptide fragment which has been bound with the MHC class I molecule in a cancer cell, moved to the surface of the cancer cell, and presented as an antigen bound to the MHC class I molecule on the cancer cell surface. The peptide becomes a mark of the cancer cell. The HER2/neu E75 peptide, which is a HLA-A2 or A3 haplotype MHC restricted peptide, is considered as a particularly 25 promising HER2/neu peptide because it is reported to be effective in clinical tests. The amino acid sequence of the HER2/neu E75 peptide is Lys-Ile-Phe-Gly-Ser-Leu-Ala-Phe-Leu (SEQ ID NO: 1). When HER2/neu E75 peptide, or a modified HER2/neu E75 peptide in which a part of amino acids of the HER2/neu E75 peptide is substituted or modified is administered to a living body as an antigen (herein, the HER2/neu E75 peptide or modified HER2/neu E75 peptide which has been administered as an antigen is referred to as "E75 antigen peptide"), the E75 antigen peptide is bound 30 to the MHC class I molecule on the surface of a dendritic cell which is an antigen presenting cell, or the E75 antigen peptide is once taken into a dendritic cell, bound to the MHC class I molecule of the dendritic cell, and then, is moved to the surface of the dendritic cell, thereby, is presented as an antigen bound to the MHC class I molecule on the surface of the dendritic cell. An activated dendritic cell having the E75 antigen peptide/MHC class I molecule complex is moved to the regional lymph node, and activates a CD8-positive T lymphocyte which recognizes the E75 antigen peptide/MHC 35 class I molecule complex to differentiate and proliferate the CD8-positive T lymphocyte into a cytotoxic T-cell (CTL). The CTL recognizes tumor cells having the complex of HER2/neu E75 peptide (derived from the endogenous HER2/neu protein) of the same amino acid sequence as the E75 antigen peptide and the MHC class I molecule; or a tumor cell having a complex of HER2/neu E75 peptide (derived from the endogenous HER2/neu protein) of an amino acid sequence having cross immunoreactivity with the E75 antigen peptide and the MHC class I molecule, and attacks the recognized 40 tumor cells. Therefore, the HER2/neu E75 peptide, and the modified HER2/neu E75 peptide in which a part of amino acids thereof are substituted or modified are useful as cancer vaccines. [0004] It is also known that an adjuvant is utilized in order to enhance the action as cancer vaccine of the HER2/neu E75 peptide. The HER2/neu E75 peptide has been investigated and reported to involve immunization by injection, and GM-CSF is known as an adjuvant to be used on that occasion. 45 [0005] In general, vaccines are administered by subcutaneous or intradermal injection. In addition to those routes, immunity induction by a various of administration route, for example, transdermal administration (Patent Document 1 and Non-Patent Document 1); and mucosal administration such as buccal administration, nasal administration, and sublingual administration (Non-Patent Document 2, Patent Document 2, and Patent Document 3) have been tried. 50 LIST OF DOCUMENTS [0006] [Patent Document 1] US Patent Application Publication No. US 2008/0193487 55 [Patent Document 2] JP 2002-531415 A [Patent Document 3] US Patent Application Publication No. US 2008/0112974 [Patent Document 4] JP 7-505883 A [Patent Document 5] JP 2007-529531 A 2 EP 2 762 161 A1 [Non-Patent Document 1] Hosoi Akihiro et al., Cancer Research, 68, 3941-3949 (2008) [Non-Patent Document 2] Zhengrong Cui et al., Pharmaceutical Research, Vol. 19, No. 7, 947-953 (2002) [Non-Patent Document 3] Mittendorf EA et al., Cancer Immunol Immunother., 57(10), 1511-1521 (2008) [Non-Patent Document 4] George EP et al., Journal of Clinical Oncology, 23(30), 7536-7545 (2005) 5 SUMMARY OF THE INVENTION [0007] It is well known that an adjuvant is used to enhance efficacy of a vaccine. Suitable adjuvant generally vary depending on, for example, the kind of the antigen, the administration route, and the immune response which is desired 10 to be induced (that is, cellular immunity or humoral immunity). Further, in addition to the adjuvant, there are a variety of substances which promote the induction of the immunity. Thus, an object of the present invention is to provide a com- position for use as a cancer vaccine, which has higher efficacy and is convenient for use. [0008] A microorganism or a virus itself, or a part of them is contained in a widely used vaccine and the vaccine is administered to induce immune response. Usually, since invasion of the microorganism or virus is inhibited by the skin 15 due to the size thereof, it is difficult that the vaccine is administered on the skin. Furthermore, it is also difficult to adm inister the vaccine orally because the microorganism or virus is decomposed by gastric acid and digestive enzymes. Therefore, injectable formulations which are invasively administered into the body have been generally utilized. However, the injection has some problems including pain, fear, injection scar, and subsequent scarring cicatrization. People other than health care workers are not permitted to perform the injection. Intradermal injection which can introduce higher 20 immune response is a difficult administration technique. There is a risk of accidental infection of the health care workers due to needlestick injury. Patients are needed to visit the hospital repeatedly when administration is performed repetitively. Medical wastes which necessitate special disposition such as injection needles are generated. In view of the above issues, injection is not necessarily the optimal administration route. [0009] A HER2/neu E75 peptide and/or a modified HER2/neu E75 peptide can activate CTLs (cytotoxic T-cells) via 25 MHC class I molecules. Furthermore, since HER2/neu E75 peptide is a molecule consisting of 9 amino acids and having a molecular weight of about 1000, and is significantly smaller than microorganisms or virus itself although they are not considered as a small molecular substance. It may be possible that they are administered by a route other than injection. However, a preparation for the administration of the peptide vaccine in a rout other than injection has not been developed yet. The reason includes many things, for example: a suitable substance that can promote to induce the cellular immunity 30 has been unknown; it has also been unknown whether or not an antigen can be delivered to a tissue suitable for the induction of the cellular immunity.
Load more

Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Protocol for a Randomised Controlled Trial: Efficacy of Donepezil Against
    BMJ Open: first published as 10.1136/bmjopen-2013-003533 on 25 September 2013. Downloaded from Open Access Protocol Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson’s disease (EDAP) Hideyuki Sawada, Tomoko Oeda To cite: Sawada H, Oeda T. ABSTRACT ARTICLE SUMMARY Protocol for a randomised Introduction: Psychosis, including hallucinations and controlled trial: efficacy of delusions, is one of the important non-motor problems donepezil against psychosis Strengths and limitations of this study in patients with Parkinson’s disease (PD) and is in Parkinson’s disease ▪ In previous randomised controlled trials for (EDAP). BMJ Open 2013;3: possibly associated with cholinergic neuronal psychosis the efficacy was investigated in patients e003533. doi:10.1136/ degeneration. The EDAP (Efficacy of Donepezil against who presented with psychosis and the primary bmjopen-2013-003533 Psychosis in PD) study will evaluate the efficacy of endpoint was improvement of psychotic symp- donepezil, a brain acetylcholine esterase inhibitor, for toms. By comparison, this study is designed to prevention of psychosis in PD. ▸ Prepublication history for evaluate the prophylactic effect in patients this paper is available online. Methods and analysis: Psychosis is assessed every without current psychosis. Because psychosis To view these files please 4 weeks using the Parkinson Psychosis Questionnaire may be overlooked and underestimated it is visit the journal online (PPQ) and patients with PD whose PPQ-B score assessed using a questionnaire, Parkinson (http://dx.doi.org/10.1136/ (hallucinations) and PPQ-C score (delusions) have Psychosis Questionnaire (PPQ) every 4 weeks. bmjopen-2013-003533). been zero for 8 weeks before enrolment are ▪ The strength of this study is its prospective randomised to two arms: patients receiving donepezil design using the preset definition of psychosis Received 3 July 2013 hydrochloride or patients receiving placebo.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest Et A1
    US007964607B2 (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest et a1. (45) Date of Patent: Jun. 21, 2011 (54) PYRAZOLO[3,4-D]PYRIMIDINE FOREIGN PATENT DOCUMENTS COMPOUNDS EP 1460077 9/2004 WO 02085904 10/2002 (75) Inventors: Patrick Robert Verhoest, Old Lyme, CT WO 2004037176 5/2004 (US); Caroline ProulX-Lafrance, Ledyard, CT (US) OTHER PUBLICATIONS Wunder et a1, M01. PharmacoL, v01. 28, N0. 6, (2005), pp. 1776 (73) Assignee: P?zer Inc., New York, NY (U S) 1781. van der Staay et a1, Neuropharmacology, v01. 55 (2008), pp. 908 ( * ) Notice: Subject to any disclaimer, the term of this 918. patent is extended or adjusted under 35 USC 154(b) by 562 days. Primary Examiner * Susanna Moore (74) Attorney, Agent, or Firm * Jennifer A. Kispert; (21) Appl.No.: 12/118,062 Michael Herman (22) Filed: May 9, 2008 (57) ABSTRACT (65) Prior Publication Data The invention provides PDE9-inhibiting compounds of For US 2009/0030003 A1 Jan. 29, 2009 mula (I), Related US. Application Data (60) Provisional application No. 60/917,333, ?led on May 11, 2007. (51) Int. Cl. C07D 48 7/04 (2006.01) A61K 31/519 (2006.01) A61P 25/28 (2006.01) (52) US. Cl. ................................... .. 514/262.1; 544/262 (58) Field of Classi?cation Search ................ .. 544/262; 5 1 4/2 62 .1 See application ?le for complete search history. and pharmaceutically acceptable salts thereof, Wherein R, R1, (56) References Cited R2 and R3 are as de?ned herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in U.S.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from Treatment of stable chronic obstructive pulmonary disease: a protocol for a systematic review and evidence map Journal: BMJ Open ManuscriptFor ID peerbmjopen-2018-027935 review only Article Type: Protocol Date Submitted by the 15-Nov-2018 Author: Complete List of Authors: Dobler, Claudia; Mayo Clinic, Evidence-Based Practice Center, Robert D.
    [Show full text]
  • Use of Anticholinergic Drugs in Patients with Schizophrenia in Asia from 2001 to 2009
    114 Original Paper Use of Anticholinergic Drugs in Patients with Schizophrenia in Asia from 2001 to 2009 Authors Y.-T. Xiang 1 , 2 , C.-Y. Wang 2 , T.-M. Si 3 , E. H. M. Lee 1 , Y.-L. He 4 , G. S. Ungvari 5 , H. F. K. Chiu1 , S.-Y. Yang 6 , M.-Y. Chong 7 , C.-H. Tan 8 , E.-H. Kua 8 , S. Fujii 9 , K. Sim 10 , K. H. Yong 10 , J. K. Trivedi 11 , E.-K. Chung 12 , P. Udomratn 13 , K.-Y. Chee 14 , N. Sartorius 15 , N. Shinfuku 16 Affi liations A ffi liation addresses are listed at the end of the article Abstract variations at each time period. Multiple logistic ▼ regression analysis of the whole sample showed Objective: The aim of this study was to survey that patients taking ACM presented with more the use of anticholinergic medication (ACM) in severe positive, negative, and extrapyramidal Asia between 2001 and 2009 and examine its symptoms. They were also more likely to receive demographic and clinical correlates. fi rst-generation and depot antipsychotics and Method: A total of 6 761 hospitalized schizo- antipsychotic polypharmacy, and less likely to phrenia patients in 9 Asian countries and terri- receive second-generation ones. tories were examined between 2001 and 2009. Conclusions: The wide variation in ACM pre- The patients ’ socio-demographic and clinical scription across Asia suggests that a combination received 24.12.2010 characteristics and the prescriptions of psycho- of clinical, social, economic and cultural fac- revised 04.03.2011 tropic drugs were recorded using a standardized tors play a role in determining the use of these accepted 09.03.2011 protocol and data collection procedure.
    [Show full text]
  • WO 2018/023009 Al 01 February 2018 (01.02.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2018/023009 Al 01 February 2018 (01.02.2018) W !P O PCT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, C07D 417/14 (2006.01) A61K 31/496 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, A61P 25/18 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (21) International Application Number: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, PCT/US20 17/044400 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 28 July 2017 (28.07.2017) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 62/368,630 29 July 2016 (29.07.2016) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicant: CONCERT PHARMACEUTICALS, INC.
    [Show full text]
  • Serotonergic System Modulation Holds Promise for L‐Dopa‐Induced Dyskinesias in Hemiparkinsonian Rats: a Systematic Review
    EXCLI Journal 2020;19:268-295 – ISSN 1611-2156 Received: January 03, 2020, accepted: February 24, 2020, published: March 02, 2020 Review article: SEROTONERGIC SYSTEM MODULATION HOLDS PROMISE FOR L‐DOPA‐INDUCED DYSKINESIAS IN HEMIPARKINSONIAN RATS: A SYSTEMATIC REVIEW Fereshteh Farajdokht1, 2, Saeed Sadigh-Eteghad2, Alireza Majdi2, Fariba Pashazadeh1,3, Seyyed Mehdi Vatandoust2, Mojtaba Ziaee4,5, Fatemeh Safari6, Pouran Karimi2, Javad Mahmoudi2* 1 Research Center for Evidence-Based Medicine (EBM), Health Management and Safety Promotion Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran 2 Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran 3 Iranian Evidence-Based Medicine (EBM) Center, a Joanna Briggs Institute Affiliated Group 4 Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 5 Phytopharmacology Research Center, Maragheh University of Medical Sciences, Maragheh, Iran 6 Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran * Corresponding author: Dr. Javad Mahmoudi, Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran, Postal code: 5166614756, Iran, Tel: +984133351284, E-mails: [email protected], [email protected] http://dx.doi.org/10.17179/excli2020-1024 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/). ABSTRACT The alleged effects of serotonergic agents in alleviating levodopa-induced dyskinesias (LIDs) in parkinsonian patients are debatable. To this end, we systematically reviewed the serotonergic agents used for the treatment of LIDs in a 6-hydroxydopamine model of Parkinson’s disease in rats. We searched MEDLINE via PubMed, Embase, Google Scholar, and Proquest for entries no later than March 2018, and restricted the search to publications on serotonergic agents used for the treatment of LIDs in hemiparkinsonian rats.
    [Show full text]
  • Common Use of High Doses of Antipsychotic Medications in Older Asian Patients with Schizophrenia (2001–2009)
    RESEARCH ARTICLE Common use of high doses of antipsychotic medications in older Asian patients with schizophrenia (2001–2009) † Yu-Tao Xiang1,2, , Yan Li1, Christoph U. Correll3, Gabor S. Ungvari4,5, Helen F.K. Chiu1, Kelly Y. C. Lai1, † Quan-Sheng Tang6,7, , Wei Hao6, Tian-Mei Si8, Chuan-Yue Wang2, Edwin H. M Lee9, Yan-Ling He10, Shu-Yu Yang11, Mian-Yoon Chong12, Ee-Heok Kua13, Senta Fujii14, Kang Sim15, Michael K.H. Yong16, Jitendra K. Trivedi17, Eun-Kee Chung18, Pichet Udomratn19, Kok-Yoon Chee20, Norman Sartorius21, Chay-Hoon Tan22 and Naotaka Shinfuku23 1Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, China 2Beijing Anding Hospital, Capital Medical University, Beijing, China 3Division of Psychiatry Research, The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Glen Oaks, NY, USA 4School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, Australia 5The University of Notre Dame Australia/Marian Centre, Perth, Australia 6Mental Health Institute, Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China 7Nanning Red Cross Hospital, Nanning, Guangxi Province, China 8The Key Laboratory of Mental Health, Ministry of Mental Health and Peking University Institute of Mental Health, Beijing, China 9Department of Psychiatry, University of Hong Kong, Hong Kong, China 10Department of Psychiatric Epidemiology, Shanghai Mental Health Center, Shanghai, China 11Department of Pharmacy, Taipei City Hospital, Taipei, Taiwan 12Kaohsiung Chang Gung Memorial Hospital and Chang Gung University School of Medicine, Kaohsiung, Taiwan 13Department of Psychological Medicine, National University of Singapore, Singapore, Singapore 14Hyogo Institute for Traumatic Stress (HITS), Kobe, Japan 15Department of General Psychiatry, Institute of Mental Health, Buangkok View, Singapore, Singapore 16Department of Medicine, Alexandra Hospital/Jurong Health Services, Singapore 17Department of Psychiatry, C.S.M.
    [Show full text]